{"transactions":[{"id":914104,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":33.2,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914103,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":48.3,"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914102,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1920,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":61.9,"underlying":"Common Stock","underlying_shares":1920},"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914101,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":265.9,"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914100,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":190,"underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914099,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an \"In-The-Money Option\"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.874,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914098,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":7283,"ownership":{"direct":false,"nature":"By Quinn Family Irrevocable Trust of 2021"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the \"Quinn Family Trust\"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":914097,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T17:40:10.000Z","date":"2026-02-09","kind":"other","planned":false,"acquired":false,"shares":29928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among Generation Bio. Co. (the \"Issuer\"), XOMA Royalty Corporation (\"Parent\") and Parent's wholly-owned subsidiary, XRA 7 Corp. (\"Merger Sub\"), dated as of December 15, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the \"Cash Amount\"), plus (ii) one non-tradeable contingent value right per Share (the \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-012194","document":"tm265471-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000110465926012194/tm265471-9_4seq1.xml","form_type":"4"}},{"id":1119251,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T16:05:26.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders."}],"balance_after":30000,"derivative":{"exercise_price":0.3874,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-015958","document":"form4-06062025_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588925015958/form4-06062025_040606.xml","form_type":"4"}},{"id":1303188,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T16:05:17.000Z","date":"2025-01-13","kind":"purchase","planned":false,"acquired":true,"shares":85000,"price":0.97,"value":82450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.93 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":299286,"source":{"system":"sec-edgar","filing":"0001415889-25-001417","document":"form4-01142025_040110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588925001417/form4-01142025_040110.xml","form_type":"4"}},{"id":1303187,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-14T16:05:17.000Z","date":"2025-01-10","kind":"purchase","planned":false,"acquired":true,"shares":125791,"price":0.96,"value":120759.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.92 to $0.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":214286,"source":{"system":"sec-edgar","filing":"0001415889-25-001417","document":"form4-01142025_040110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588925001417/form4-01142025_040110.xml","form_type":"4"}},{"id":1484528,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T16:05:22.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders."}],"balance_after":60000,"derivative":{"exercise_price":3.32,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-24-016184","document":"form4-06102024_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588924016184/form4-06102024_040615.xml","form_type":"4"}},{"id":1721144,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T16:30:36.000Z","date":"2023-12-01","kind":"purchase","planned":false,"acquired":true,"shares":88495,"price":1.41,"value":124777.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":88495,"source":{"system":"sec-edgar","filing":"0001415889-23-015857","document":"form4-12052023_041204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588923015857/form4-12052023_041204.xml","form_type":"4"}},{"id":1858395,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T16:15:21.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders."}],"balance_after":25000,"derivative":{"exercise_price":4.83,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009609","document":"form4-06122023_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588923009609/form4-06122023_040614.xml","form_type":"4"}},{"id":2233702,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T16:05:14.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders."}],"balance_after":19200,"derivative":{"exercise_price":6.19,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":19200},"source":{"system":"sec-edgar","filing":"0001415889-22-006475","document":"form4-06132022_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588922006475/form4-06132022_040601.xml","form_type":"4"}},{"id":2324068,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-18T06:46:58.000Z","date":"2022-03-16","kind":"purchase","acquired":true,"shares":80079,"price":2.344,"value":187705.176,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":550540,"source":{"system":"sec-edgar","filing":"0001209191-22-019929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122019929/doc4.xml","form_type":"4"}},{"id":2332768,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-15T18:32:21.000Z","date":"2022-03-15","kind":"purchase","acquired":true,"shares":42417,"price":1.8611,"value":78942.2787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $2.00 per share, inclusive."}],"balance_after":473461,"source":{"system":"sec-edgar","filing":"0001209191-22-018942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122018942/doc4.xml","form_type":"4"}},{"id":2332767,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-15T18:32:21.000Z","date":"2022-03-14","kind":"purchase","acquired":true,"shares":67472,"price":1.93,"value":130220.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.93 per share, inclusive."}],"balance_after":431044,"source":{"system":"sec-edgar","filing":"0001209191-22-018942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122018942/doc4.xml","form_type":"4"}},{"id":2332766,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-15T18:32:21.000Z","date":"2022-03-11","kind":"purchase","acquired":true,"shares":34777,"price":2.064,"value":71779.728,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.995 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":363572,"source":{"system":"sec-edgar","filing":"0001209191-22-018942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122018942/doc4.xml","form_type":"4"}},{"id":2381647,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T16:57:09.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":350000,"derivative":{"exercise_price":3.17,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-22-011724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122011724/doc4.xml","form_type":"4"}},{"id":2397222,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2021-10-20","kind":"gift","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee."}],"balance_after":208845,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397221,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2021-10-20","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":328795,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397220,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2021-10-18","kind":"gift","acquired":true,"shares":23809,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee."}],"balance_after":208845,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397219,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2021-10-18","kind":"gift","acquired":false,"shares":23809,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":328795,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397218,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2021-10-14","kind":"gift","acquired":true,"shares":175036,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee."}],"balance_after":208845,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397217,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2021-10-14","kind":"gift","acquired":false,"shares":175036,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":328795,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397216,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2018-12-28","kind":"gift","acquired":true,"shares":57450,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held by the Anthony G. Quinn Irrevocable Trust of 2018, of which the Reporting Person's spouse is trustee."}],"balance_after":57450,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2397215,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-14T17:19:58.000Z","date":"2018-12-28","kind":"gift","acquired":false,"shares":57450,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":328795,"source":{"system":"sec-edgar","filing":"0001209191-22-009407","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919122009407/doc5.xml","form_type":"5"}},{"id":2475106,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-13T20:39:37.000Z","date":"2021-12-10","kind":"purchase","acquired":true,"shares":10526,"price":3.75,"value":39472.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.62 to $3.80 per share, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":328795,"source":{"system":"sec-edgar","filing":"0001209191-21-069350","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919121069350/doc4.xml","form_type":"4"}},{"id":2475105,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-13T20:39:37.000Z","date":"2021-12-09","kind":"purchase","acquired":true,"shares":43108,"price":3.7,"value":159499.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":318269,"source":{"system":"sec-edgar","filing":"0001209191-21-069350","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919121069350/doc4.xml","form_type":"4"}},{"id":2531623,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-29T16:01:38.000Z","date":"2021-10-28","kind":"gift","acquired":true,"shares":72837,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person gifted these shares to the Spousal Lifetime Access Trust (the \"Trust\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by the Trust. The reporting person is the settlor of the Trust, M. Clare Quinn is the trustee for the Trust and the Trust is for the benefit of Emma, Richard, and Charles Quinn. The reporting person may be deemed to beneficially own the shares of common stock owned by the Trust."}],"balance_after":72837,"source":{"system":"sec-edgar","filing":"0001415889-21-005028","document":"form4-10292021_011020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588921005028/form4-10292021_011020.xml","form_type":"4"}},{"id":2531622,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-29T16:01:38.000Z","date":"2021-10-28","kind":"gift","acquired":false,"shares":72837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person gifted these shares to the Spousal Lifetime Access Trust (the \"Trust\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-21-005028","document":"form4-10292021_011020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588921005028/form4-10292021_011020.xml","form_type":"4"}},{"id":2647811,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T16:22:33.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15000,"derivative":{"exercise_price":7.44,"exercise_date":"2022-06-30","expiration_date":"2031-06-29","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-044388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000120919121044388/doc4.xml","form_type":"4"}},{"id":2671371,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T16:08:23.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":26.59,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-21-002949","document":"form4-06112021_010609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000141588921002949/form4-06112021_010609.xml","form_type":"4"}},{"id":2845580,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-19T17:08:14.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2021, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":330000,"derivative":{"exercise_price":7.35,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001209191-21-012424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919121012424/doc4.xml","form_type":"4"}},{"id":3095409,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-01T16:16:06.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15000,"derivative":{"exercise_price":7.43,"exercise_date":"2021-06-30","expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-039724","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000120919120039724/doc4.xml","form_type":"4"}},{"id":3105090,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-06-18T17:31:29.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":53654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":30376},"source":{"system":"sec-edgar","filing":"0000899243-20-017107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000089924320017107/doc4.xml","form_type":"4"}},{"id":3105089,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T17:31:29.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":30376,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":72837,"source":{"system":"sec-edgar","filing":"0000899243-20-017107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000089924320017107/doc4.xml","form_type":"4"}},{"id":3110106,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T17:23:55.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":19,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000899243-20-016553","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000089924320016553/doc4.xml","form_type":"4"}},{"id":3163357,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-04T07:30:14.000Z","date":"2020-04-30","kind":"purchase","acquired":true,"shares":165000,"price":4.75,"value":783750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 788 shares acquired by the Reporting Person on August 15, 2019 and 773 shares acquired by the Reporting Person on February 15, 2020 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":538469,"source":{"system":"sec-edgar","filing":"0001209191-20-026662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000120919120026662/doc4.xml","form_type":"4"}},{"id":3262152,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-19T17:13:16.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":301000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":301000,"derivative":{"exercise_price":8.15,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":301000},"source":{"system":"sec-edgar","filing":"0001567619-20-004316","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761920004316/doc1.xml","form_type":"4"}},{"id":3396475,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-10-07T16:09:24.000Z","date":"2019-10-04","kind":"exercise","acquired":false,"shares":17603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exerciseable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":119914,"derivative":{"exercise_price":6.31,"expiration_date":"2028-02-19","underlying":"Common Stock","underlying_shares":17603},"source":{"system":"sec-edgar","filing":"0001567619-19-019297","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919019297/doc1.xml","form_type":"4"}},{"id":3396474,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-10-07T16:09:24.000Z","date":"2019-10-04","kind":"exercise","acquired":false,"shares":662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested and became exerciseable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.46,"expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":662},"source":{"system":"sec-edgar","filing":"0001567619-19-019297","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919019297/doc1.xml","form_type":"4"}},{"id":3396473,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-10-07T16:09:24.000Z","date":"2019-10-04","kind":"exercise","acquired":true,"shares":17603,"price":6.31,"value":111074.93,"ownership":{"direct":true},"balance_after":371908,"source":{"system":"sec-edgar","filing":"0001567619-19-019297","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919019297/doc1.xml","form_type":"4"}},{"id":3396472,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-10-07T16:09:24.000Z","date":"2019-10-04","kind":"exercise","acquired":true,"shares":662,"price":5.46,"value":3614.52,"ownership":{"direct":true},"balance_after":354305,"source":{"system":"sec-edgar","filing":"0001567619-19-019297","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919019297/doc1.xml","form_type":"4"}},{"id":3489132,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-14T17:22:19.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":5282,"price":6.2311,"value":32912.6702,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.18 to $6.2825 per share."}],"balance_after":353643,"source":{"system":"sec-edgar","filing":"0001567619-19-013411","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919013411/doc1.xml","form_type":"4"}},{"id":3489131,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-14T17:22:19.000Z","date":"2019-06-13","kind":"purchase","acquired":true,"shares":14406,"price":6.1666,"value":88836.0396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.23 per share."}],"balance_after":348361,"source":{"system":"sec-edgar","filing":"0001567619-19-013411","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919013411/doc1.xml","form_type":"4"}},{"id":3489130,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-06-14T17:22:19.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":12217,"price":6.1148,"value":74704.5116,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.07 to $6.20 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."}],"balance_after":333955,"source":{"system":"sec-edgar","filing":"0001567619-19-013411","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919013411/doc1.xml","form_type":"4"}},{"id":3514698,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T16:55:23.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":3809,"price":6.8596,"value":26128.2164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.69 to $7.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":321738,"source":{"system":"sec-edgar","filing":"0001567619-19-011852","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011852/doc1.xml","form_type":"4"}},{"id":3514697,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T16:55:23.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":13794,"price":6.8857,"value":94981.3458,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.53 to $7.00 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":317929,"source":{"system":"sec-edgar","filing":"0001567619-19-011852","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011852/doc1.xml","form_type":"4"}},{"id":3514696,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T16:55:23.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":8989,"price":6.555,"value":58922.895,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.73 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":304135,"source":{"system":"sec-edgar","filing":"0001567619-19-011852","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011852/doc1.xml","form_type":"4"}},{"id":3520178,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-17T17:04:29.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":6218,"price":6.6477,"value":41335.3986,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.51 to $6.85 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":295146,"source":{"system":"sec-edgar","filing":"0001567619-19-011561","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011561/doc1.xml","form_type":"4"}},{"id":3520177,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-17T17:04:29.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":5520,"price":6.828,"value":37690.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.75 to $6.93 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":288928,"source":{"system":"sec-edgar","filing":"0001567619-19-011561","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011561/doc1.xml","form_type":"4"}},{"id":3520176,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-17T17:04:29.000Z","date":"2019-05-15","kind":"purchase","acquired":true,"shares":6256,"price":6.7566,"value":42269.2896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.65 to $6.87 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":283408,"source":{"system":"sec-edgar","filing":"0001567619-19-011561","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011561/doc1.xml","form_type":"4"}},{"id":3520175,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-17T17:04:29.000Z","date":"2019-02-15","kind":"purchase","acquired":true,"shares":719,"price":7.098,"value":5103.462,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":277152,"source":{"system":"sec-edgar","filing":"0001567619-19-011561","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919011561/doc1.xml","form_type":"4"}},{"id":3619522,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-03-04T20:13:26.000Z","date":"2019-03-04","kind":"exercise","acquired":false,"shares":25707,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 (\"Common Stock\"), on a one-for-two basis upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 (\"Common Stock\"), on a one-for-two basis upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 (\"Common Stock\"), on a one-for-two basis upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 (\"Common Stock\"), on a one-for-two basis upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12853},"source":{"system":"sec-edgar","filing":"0000899243-19-005963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000089924319005963/doc4.xml","form_type":"4"}},{"id":3619521,"issuer":{"id":129745,"kind":"organization","name":"Kaleido Biosciences, Inc.","symbol":"KLDO"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-04T20:13:26.000Z","date":"2019-03-04","kind":"exercise","acquired":true,"shares":12853,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 (\"Common Stock\"), on a one-for-two basis upon the closing of the Issuer's initial public offering."}],"balance_after":31603,"source":{"system":"sec-edgar","filing":"0000899243-19-005963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751299/000089924319005963/doc4.xml","form_type":"4"}},{"id":3622699,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-01T17:08:19.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":280000,"derivative":{"exercise_price":8.36,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001567619-19-005835","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919005835/doc1.xml","form_type":"4"}},{"id":3667648,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T16:15:21.000Z","date":"2019-02-06","kind":"exercise","acquired":false,"shares":7433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":137517,"derivative":{"exercise_price":6.31,"expiration_date":"2028-02-19","underlying":"Common Stock","underlying_shares":7433},"source":{"system":"sec-edgar","filing":"0001567619-19-002796","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919002796/doc1.xml","form_type":"4"}},{"id":3667647,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T16:15:21.000Z","date":"2019-02-06","kind":"exercise","acquired":false,"shares":1323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":662,"derivative":{"exercise_price":5.46,"expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":1323},"source":{"system":"sec-edgar","filing":"0001567619-19-002796","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919002796/doc1.xml","form_type":"4"}},{"id":3667646,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-08T16:15:21.000Z","date":"2019-02-06","kind":"exercise","acquired":true,"shares":7433,"price":6.31,"value":46902.23,"ownership":{"direct":true},"balance_after":276433,"source":{"system":"sec-edgar","filing":"0001567619-19-002796","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919002796/doc1.xml","form_type":"4"}},{"id":3667645,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-08T16:15:21.000Z","date":"2019-02-06","kind":"exercise","acquired":true,"shares":1323,"price":5.46,"value":7223.58,"ownership":{"direct":true},"balance_after":269000,"source":{"system":"sec-edgar","filing":"0001567619-19-002796","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761919002796/doc1.xml","form_type":"4"}},{"id":3737216,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-12-10T17:40:07.000Z","date":"2018-12-07","kind":"exercise","acquired":false,"shares":18584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":144950,"derivative":{"exercise_price":6.31,"expiration_date":"2028-02-19","underlying":"Common Stock","underlying_shares":18584},"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737215,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-12-10T17:40:07.000Z","date":"2018-12-07","kind":"exercise","acquired":false,"shares":3306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":1985,"derivative":{"exercise_price":5.46,"expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":3306},"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737214,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-12-10T17:40:07.000Z","date":"2018-12-07","kind":"exercise","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested and became exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.11,"expiration_date":"2027-08-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737213,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-10T17:40:07.000Z","date":"2018-12-07","kind":"exercise","acquired":true,"shares":18584,"price":6.31,"value":117265.04,"ownership":{"direct":true},"balance_after":267677,"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737212,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-10T17:40:07.000Z","date":"2018-12-07","kind":"exercise","acquired":true,"shares":3306,"price":5.46,"value":18050.76,"ownership":{"direct":true},"balance_after":249093,"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737211,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-10T17:40:07.000Z","date":"2018-12-07","kind":"exercise","acquired":true,"shares":150000,"price":4.11,"value":616500.0,"ownership":{"direct":true},"balance_after":245787,"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737210,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-10T17:40:07.000Z","date":"2018-08-15","kind":"purchase","acquired":true,"shares":994,"price":9.13,"value":9075.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":95787,"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3737209,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-10T17:40:07.000Z","date":"2018-02-15","kind":"purchase","acquired":true,"shares":2000,"price":6.02,"value":12040.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":94793,"source":{"system":"sec-edgar","filing":"0001567619-18-007640","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000156761918007640/doc1.xml","form_type":"4"}},{"id":3863420,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-07-20T17:26:16.000Z","date":"2018-07-18","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests and becomes exercisable contingent upon achievement of certain regulatory milestones."}],"balance_after":50000,"derivative":{"exercise_price":9.36,"expiration_date":"2028-07-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-18-033053","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118033053/doc1.xml","form_type":"4"}},{"id":3863419,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-07-20T17:26:16.000Z","date":"2018-07-18","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests and becomes exercisable contingent upon achievement of certain product development milestones."}],"balance_after":75000,"derivative":{"exercise_price":9.36,"expiration_date":"2028-07-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001140361-18-033053","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118033053/doc1.xml","form_type":"4"}},{"id":3863418,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-07-20T17:26:16.000Z","date":"2018-07-18","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable contingent upon achievement of certain stock price milestones."}],"balance_after":75000,"derivative":{"exercise_price":9.36,"expiration_date":"2028-07-17","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001140361-18-033053","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118033053/doc1.xml","form_type":"4"}},{"id":3863417,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-07-20T17:26:16.000Z","date":"2018-07-18","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on August 18, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":300000,"derivative":{"exercise_price":9.36,"expiration_date":"2028-07-17","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001140361-18-033053","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118033053/doc1.xml","form_type":"4"}},{"id":3867152,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-07-16T09:04:32.000Z","date":"2018-07-12","kind":"exercise","acquired":false,"shares":14866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":163534,"derivative":{"exercise_price":6.31,"expiration_date":"2028-02-19","underlying":"Common Stock","underlying_shares":14866},"source":{"system":"sec-edgar","filing":"0001140361-18-032462","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118032462/doc1.xml","form_type":"4"}},{"id":3867151,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-07-16T09:04:32.000Z","date":"2018-07-12","kind":"exercise","acquired":false,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.04,"expiration_date":"2027-04-20","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001140361-18-032462","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118032462/doc1.xml","form_type":"4"}},{"id":3867150,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2018-07-16T09:04:32.000Z","date":"2018-07-12","kind":"exercise","acquired":true,"shares":14866,"price":6.31,"value":93804.46,"ownership":{"direct":true},"balance_after":92793,"source":{"system":"sec-edgar","filing":"0001140361-18-032462","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118032462/doc1.xml","form_type":"4"}},{"id":3867149,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2018-07-16T09:04:32.000Z","date":"2018-07-12","kind":"exercise","acquired":true,"shares":24000,"price":7.04,"value":168960.0,"ownership":{"direct":true},"balance_after":77927,"source":{"system":"sec-edgar","filing":"0001140361-18-032462","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118032462/doc1.xml","form_type":"4"}},{"id":3867856,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-07-13T09:05:43.000Z","date":"2018-07-11","kind":"exercise","acquired":false,"shares":3307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":5291,"derivative":{"exercise_price":5.46,"expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":3307},"source":{"system":"sec-edgar","filing":"0001140361-18-032316","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118032316/doc1.xml","form_type":"4"}},{"id":3867855,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2018-07-13T09:05:43.000Z","date":"2018-07-11","kind":"exercise","acquired":true,"shares":3307,"price":5.46,"value":18056.22,"ownership":{"direct":true},"balance_after":53927,"source":{"system":"sec-edgar","filing":"0001140361-18-032316","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118032316/doc1.xml","form_type":"4"}},{"id":4039541,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-02-22T18:23:29.000Z","date":"2018-02-20","kind":"grant","acquired":true,"shares":178400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":178400,"derivative":{"exercise_price":6.31,"expiration_date":"2028-02-19","underlying":"Common Stock","underlying_shares":178400},"source":{"system":"sec-edgar","filing":"0001140361-18-009665","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118009665/doc1.xml","form_type":"4"}},{"id":4046831,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Director Stock Option (right to buy)","published_at":"2018-02-20T16:36:26.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":15211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":8598,"derivative":{"exercise_price":5.46,"expiration_date":"2026-03-17","underlying":"Common Stock","underlying_shares":15211},"source":{"system":"sec-edgar","filing":"0001140361-18-009074","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118009074/doc1.xml","form_type":"4"}},{"id":4046830,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2018-02-20T16:36:26.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":15211,"price":5.46,"value":83052.06,"ownership":{"direct":true},"balance_after":50620,"source":{"system":"sec-edgar","filing":"0001140361-18-009074","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036118009074/doc1.xml","form_type":"4"}},{"id":4137635,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2017-12-08T19:06:50.000Z","date":"2017-12-08","kind":"purchase","acquired":true,"shares":600,"price":5.065,"value":3039.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $5.01 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":35409,"source":{"system":"sec-edgar","filing":"0001140361-17-045528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117045528/doc1.xml","form_type":"4"}},{"id":4137634,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2017-12-08T19:06:50.000Z","date":"2017-12-07","kind":"purchase","acquired":true,"shares":2800,"price":4.9882,"value":13966.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.88 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":34809,"source":{"system":"sec-edgar","filing":"0001140361-17-045528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117045528/doc1.xml","form_type":"4"}},{"id":4137633,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Common Stock","published_at":"2017-12-08T19:06:50.000Z","date":"2017-12-06","kind":"purchase","acquired":true,"shares":4888,"price":4.9248,"value":24072.4224,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.77 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":32009,"source":{"system":"sec-edgar","filing":"0001140361-17-045528","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117045528/doc1.xml","form_type":"4"}},{"id":4141466,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-05T21:04:41.000Z","date":"2017-12-05","kind":"purchase","acquired":true,"shares":5065,"price":4.931,"value":24975.515,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.70 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":27121,"source":{"system":"sec-edgar","filing":"0001140361-17-045127","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117045127/doc1.xml","form_type":"4"}},{"id":4141465,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-05T21:04:41.000Z","date":"2017-12-04","kind":"purchase","acquired":true,"shares":7956,"price":4.9804,"value":39624.0624,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.85 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":22056,"source":{"system":"sec-edgar","filing":"0001140361-17-045127","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117045127/doc1.xml","form_type":"4"}},{"id":4141464,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-05T21:04:41.000Z","date":"2017-12-01","kind":"purchase","acquired":true,"shares":4100,"price":4.5312,"value":18577.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.29 to $4.60 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":14100,"source":{"system":"sec-edgar","filing":"0001140361-17-045127","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117045127/doc1.xml","form_type":"4"}},{"id":4219522,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-09-01T17:10:42.000Z","date":"2017-08-31","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 100% of the shares subject to the option on July 18, 2018, subject to the continuing service of the Reporting Person on the vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.11,"expiration_date":"2027-08-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001140361-17-034179","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117034179/doc1.xml","form_type":"4"}},{"id":4345401,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":67189,"kind":"person","name":"Quinn Anthony G.","position":1,"cik":"0001532219","reported_name":"Quinn Anthony","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"interim Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-04-25T17:10:32.000Z","date":"2017-04-21","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three equal monthly installments beginning on May 21, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":24000,"derivative":{"exercise_price":7.04,"expiration_date":"2027-04-20","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001140361-17-016748","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1532219/000114036117016748/doc1.xml","form_type":"4"}}]}